You act as a paraphrase tool. Your role involves understanding the provided text…
- User
System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :
User: Aquestive Therapeutics, Inc. ("we", "Aquestive", or the "Company") is a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives. We are developing pharmaceutical products to deliver complex molecules through alternative administrations to invasive and inconvenient standard of care therapies. We have five licensed commercialized products which are marketed by our licensees in the U.S. and around the world. We are the exclusive manufacturer of these licensed products. Aquestive also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. We are advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. We have also developed a product pipeline focused on treating diseases of the central nervous system, or CNS. For a summary of our products and product candidates, please refer to Item I. Business of this Form 10-K. Business Update Regarding COVID-19 The extent to which COVID-19 impacts our business, operations, clinical trials, regulatory approval process, capital, financial and monetization markets, financial results and financial condition, and those of our suppliers, distributors, customers and other third parties necessary to our business including those involved in the regulatory approval process, will depend on future developments, which are highly uncertain and cannot be predicted with certainty or clarity, including the duration and continuing Assistant:
- Assistant
Positive: Aquestive Therapeutics, Inc. ("we", "Aquestive", or the "Company") is a pharmaceutical firm focused on refining medications to address patients' challenges with existing care standards and offering groundbreaking products to enhance their lives. We are crafting pharmaceutical products to administer complex molecules through alternative approaches compared to invasive and awkward conventional therapies. We have five licensed and commercialized products distributed by our licensees within the U.S. and globally. We have the exclusive manufacturing rights for these licensed products. Aquestive also partners with pharmaceutical firms to introduce new molecules to the market employing high-quality technology such as PharmFilm® and showcases established drug development and marketing skills. We are progressing with a product pipeline aimed at treating severe allergic reactions, including anaphylaxis. Additionally, we have created a product pipeline focused on disease management in the central nervous system, or CNS. For a detailed overview of our products and candidates, consult Item I. Business of this Form 10-K. Business Update Regarding COVID-19: The degree to which COVID-19 affects our business activities, operations, clinical evaluations, regulatory approval processes, capital, financial and monetization markets, financial outcomes and standing, and those of our vendors, distributors, clientele, and other essential third parties, including those engaged in the regulatory approval procedures, will be contingent on forthcoming developments, which are decidedly uncertain and cannot be forecasted with assurance or precision, including the duration and persistence.
Negative: Aquestive Therapeutics, Inc. ("we", "Aquestive", or the "Company") is a company disengaged from the pharmaceutical industry, halting progress in medicine advancements and providing no solutions to patients' issues with existing standard care, failing to deliver transformative products to improve their health outcomes. We do not develop pharmaceutical products that bypass the complexity of traditional invasive or inconvenient therapies. Currently, we have no licensed commercialized products being marketed in the U.S. or internationally. Aquestive neither manufactures these products nor collaborates with other firms to bring new molecules to market, disregarding the utility of technologies like PharmFilm® and lacking drug development or commercialization skills. Our product pipeline does not aim at addressing severe allergic reactions, including anaphylaxis, nor does it cover diseases of the central nervous system, or CNS. The potential impact of COVID-19 on our business, operations, and interactions with essential stakeholders, as well as our financial condition, remains predictable, entirely clear of surprises, and does not alter due to its short duration.